Cargando…

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than 15 different ALK fusion partners have been discovered in NSCLC patients. Most of these ALK fusions responded well to the ALK inhibitor crizo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Xue, Shao, Yun, Gao, Hongjun, Zhang, Xueli, Zhang, Han, Ban, Yi, Qin, Haifeng, Tai, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Bedside to Bench Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301797/ https://www.ncbi.nlm.nih.gov/pubmed/30273505 http://dx.doi.org/10.1080/15384047.2018.1480282

Ejemplares similares

Current progress in ABO-incompatible kidney transplantation
por: Koo, Tai Yeon, et al.
Publicado: (2015)

Endovascular interventions for central vein stenosis
por: Agarwal, Anil K.
Publicado: (2015)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
por: Zhu, You-cai, et al.
Publicado: (2018)

RNA sequencing of the nephron transcriptome: a technical note
por: Lee, Jae Wook
Publicado: (2015)

Organ-on-a-chip and the kidney
por: Kim, Sejoong, et al.
Publicado: (2015)

Neuro-tracing approach to study kidney innervation: a technical note
por: Lee, Sanghee, et al.
Publicado: (2017)

Messenger RNA vaccines against SARS-CoV-2
por: Topol, Eric J.
Publicado: (2021)

A novel break site of EML4‐ALK report and a rare PRKAR1A‐ALK report analyzed by different ALK detection platforms in non‐small cell lung cancer patients
por: Du, Xue, et al.
Publicado: (2021)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib
por: Deland, Lily, et al.
Publicado: (2021)

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report
por: Wu, Xuan, et al.
Publicado: (2020)

A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report
por: Guo, Jun, et al.
Publicado: (2020)

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
por: Tao, Hong, et al.
Publicado: (2022)

De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
por: Li, Jing-Wen, et al.
Publicado: (2019)

Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
por: Lipkin, Jacob S, et al.
Publicado: (2015)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021)

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy
por: Wyluda, Edward J, et al.
Publicado: (2015)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy
por: Zhang, Bin, et al.
Publicado: (2016)

HIF2A germline–mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma
por: Liu, Qiuli, et al.
Publicado: (2017)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy
por: Liu, Qiuli, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Dramatic response to local radiotherapy in a refractory metastatic mediastinal yolk sac tumor patient harboring a germline BRCA2 frameshift mutation: a case report
por: Cheng, Xi, et al.
Publicado: (2022)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Sequential therapy with crizotinib and a second-generation ALK inhibitor versus direct therapy of a second-generation ALK inhibitor in ALK-positive advanced lung cancer: a real-world study
por: Wei, Jingwen, et al.
Publicado: (2023)

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: A case report
por: Capalbo, Carlo, et al.
Publicado: (2014)

Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
por: Graziano, Vincenzo, et al.
Publicado: (2015)

Metformin: a modulator of bevacizumab activity in cancer? A case report
por: Indraccolo, Stefano, et al.
Publicado: (2015)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach
por: Caggiari, Laura, et al.
Publicado: (2017)

Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing
por: Yang, Shanshan, et al.
Publicado: (2017)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

Successful treatment using apatinib in intractable brain edema: A case report and literatures review
por: Song, Yanqiu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_01t6m15u8km8erkmkh170jsj1r